Procter & Gamble Health (P&G Health) is one of India's largest VMS (Vitamins, Minerals, and Supplements) companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. The company operates as a specialized healthcare subsidiary, focusing on the nutritional and wellness segment of the Indian market.
P&G Health has established itself as a prominent player in the Indian healthcare sector, leveraging the global expertise and reputation of its parent company, The Procter & Gamble Company. The company's product portfolio addresses various health and wellness needs, ranging from essential vitamins and minerals to specialized nutritional supplements that cater to different age groups and health requirements.
The company has demonstrated robust financial performance in recent quarters. Net profit of Procter & Gamble Health rose 25.56% to ₹82.33 Crore in the quarter ended September 2024, as against ₹65.57 Crore during the previous quarter ended September 2023. This significant growth in profitability reflects the company's operational efficiency and strong market positioning.
Sales rose 2.78% to ₹313.41 Crore in the quarter ended September 2024, as against ₹304.93 Crore during the previous quarter ended September 2023. While revenue growth was modest compared to profit growth, it indicates steady market demand for the company's products.
For the March 2025 quarter, the company maintained its growth trajectory. Net profit of Procter & Gamble Health rose 31.40% to ₹61.18 Crore in the quarter ended March 2025, as against ₹46.56 Crore during the previous quarter ended March 2024. Sales rose 23.17% to ₹310.99 Crore in the quarter ended March 2025, as against ₹252.48 Crore during the previous quarter ended March 2024.
- Q3 FY25 Net Profit: ₹90.90 Crore (26.13% YoY growth)
- Q3 FY25 Revenue: ₹309.77 Crore (flat YoY)
- Q4 FY25 Net Profit: ₹61.18 Crore (31.40% YoY growth)
- Q4 FY25 Revenue: ₹310.99 Crore (23.17% YoY growth)
- Q2 FY25 Net Profit: ₹82.33 Crore (25.56% YoY growth)
- Q2 FY25 Revenue: ₹313.41 Crore (2.78% YoY growth)
The Market Capitalization of Procter Gamble Health Ltd is ₹9,666 Crore As on July 03, 2025, reflecting the company's substantial market presence. The stock has shown resilience and growth potential, with Procter Gamble Health Ltd hitting a 52-week high of ₹6,175.50 on June 12, 2025, and a 52-week low of ₹4,863 on October 29, 2024.
The stock's performance over different time horizons demonstrates its appeal to investors. The stock price of Procter Gamble Health Ltd is up by 2% over the last one month. It is up by 14.74% over the last one year. This positive momentum reflects investor confidence in the company's business model and growth prospects.
The P/E ratio of Procter Gamble Health Ltd is 37.2 As on July 03, 2025, indicating that the stock trades at a premium valuation, which is typical for companies in the healthcare and wellness sector with strong growth prospects.
The company maintains an attractive dividend policy for its shareholders. The board has declared an interim dividend of ₹80 per equity share for the financial year 2024-25. The record date for the dividend will be February 21, 2025. This dividend declaration represents a significant return to shareholders and demonstrates the company's commitment to sharing profits with investors.
The current dividend yield of Procter & Gamble Health Ltd (PGHL) is 4.44. This attractive dividend yield makes the stock appealing to income-focused investors while also providing capital appreciation potential.
The company's management has outlined clear strategic priorities for sustainable growth. Milind Thatte, Managing Director, P&G Health India, said, "This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike."
This strategic approach focuses on several key areas, including product portfolio optimization, operational excellence, and organizational agility. The company's emphasis on supply network strengthening positions it well to handle market volatility and ensure consistent product availability across India.
P&G Health operates in India's growing vitamins, minerals, and supplements market, which benefits from increasing health awareness and rising disposable incomes. The company's association with the global P&G brand provides credibility and access to international best practices in product development and marketing.
The company's consistent profitability growth, combined with its strong brand portfolio and strategic focus, makes it an attractive investment option in the healthcare sector. However, investors should consider the premium valuation and monitor the company's ability to maintain growth momentum in an increasingly competitive market.
With its established market position, strong financial performance, and strategic initiatives, Procter & Gamble Health Ltd continues to be a significant player in India's healthcare and wellness industry, offering investors exposure to the country's growing health consciousness trend.
